Objective

Recent advances in automated cell based imaging, new 3D cell models; CRISPR/Cas-based genome editing and induced pluripotent stem cell technologies are converging to advance Phenotypic Drug Discovery and Target Validation studies across more complex and informative cell-based models of disease. I will describe how multiparametric high content imaging assays, quantifying multiple features at cellular and sub-cellular/organelle level, combine with novel image-informatics and machine learning methods to advance Mechanism-Of-Action studies and in vitro pharmacogenomic studies across a broader variety of phenotypes, disease models and therapeutic classes. We also demonstrate how an iterative phenotypic screening strategy applying high content cell imaging and Reverse Phase Protein Microarray (RPPA) technologies can accelerate the discovery of new chemical entities and novel drug combination strategies across 2D and 3D cell-based models of disease